STEP-HFpEF, and STEP-HFpEF DM trials. According to the analysis, semaglutide led to a 31% reduced risk of combined cardiovascular (CV) death or worsening heart failure (HF) events, based on an ...
Semaglutide and Atrial Fibrillation A subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials 5 showed that patients with aFib—45% of the STEP-HFpEF program population—have ...
Novo Nordisk has just released the results of the phase 3 STEP-HFpEF trial showing that semaglutide was able to reduce symptoms and improve exercise capacity in overweight people with heart ...
Some results have been hidden because they may be inaccessible to you